NDA 211616 · Esperion Theraps INC
Nexletol
Bempedoic Acid · Oral · Adenosine Triphosphate-Citrate Lyase Inhibitor
NovelLast checked: Nov 20, 2026Latest source record: Jan 9, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2020
Feb 21, 2020
Approved uses
4
Original approval plus efficacy supplements
Registered trials
44
16 Phase 3, 11 recruiting
FAERS reports
2,702
1,565 serious, 24 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jun 25, 2026.
NEXLETOL is indicated: to reduce the risk of major adverse cardiovascular events (cardiovascular death, myocardial infarction, stroke, or coronary revascularization) in adults at increased risk for these events who are unable to take recommended statin therapy (including those not taking a statin). as an adjunct to diet and exercise, in combination with other low-density lipoprotein cholesterol (LDL-C) lowering therapies, or alone when concomitant LDL-C lowering therapy is not possible, to reduce LDL-C in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH). NEXLETOL, an adenosine triphosphate-citrate lyase (ACL) inhibitor, is indicated: to reduce the risk of major adverse cardiovascular events (cardiovascular death, myocardial infarction, stroke, or coronary revascularization) in adults at increased risk for these events who are unable to take recommended statin therapy (including those not taking a statin). ( 1 ) as an adjunct to diet and exercise, in combination with other low-density lipoprotein cholesterol (LDL-C) lowering therapies, or alone when concomitant LDL-C lowering therapy is not possible, to reduce LDL-C in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH). ( 1 )
Mechanism: Bempedoic acid is an adenosine triphosphate-citrate lyase (ACL) inhibitor that lowers LDL-C by inhibition of cholesterol synthesis in the liver. ACL is an enzyme upstream of 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase in the cholesterol biosynthesis pathway. Bempedoic acid and its active metabolite, ESP15228, require coenzyme A (CoA) activation by very long-chain acyl-CoA synthetase 1 (ACSVL1) to ETC-1002-CoA and ESP15228-CoA, respectively. ACSVL1 is expressed primarily in the liver. Inhibition of ACL by ETC-1002-CoA results in decreased cholesterol synthesis in the liver and...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Nov 21, 2025 Supplement 24 · Efficacy LetterLabel
- Mar 22, 2024 Supplement 12 · Efficacy LabelLetter
- Mar 22, 2024 Supplement 13 · Efficacy LabelLetter
- Feb 21, 2020 Original approval · Type 1 - New Molecular Entity NovelLabelLetterReview
1 products under this application
- NEXLETOL · BEMPEDOIC ACID 180MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Bempedoic Acid" as an intervention, any sponsor and status, largest first.
- Evaluation of Major Cardiovascular Events in Participants With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or PlaceboPivotal-lookingCompleted
Esperion Therapeutics, Inc.Industry
NCT02993406 · 13,970 participants · Start Dec 22, 2016 · Primary completion Nov 7, 2022
Drug: Bempedoic acid 180 mg tablet; Matching placebo tablet · For: Cardiovascular Diseases; Statin Adverse Reaction
Sites: Birmingham, Alabama; Huntsville, Alabama; Mobile, Alabama · 1,319 sites in all
- Evaluation of Long-Term Safety and Tolerability of ETC-1002 in High-Risk Patients With Hyperlipidemia and High CV Risk (CLEAR Harmony)Pivotal-lookingCompleted
Esperion Therapeutics, Inc.Industry
NCT02666664 · 2,230 participants · Start Jan 21, 2016 · Primary completion Feb 21, 2018
Drug: ETC-1002; Placebo · For: Hypercholesterolemia; Atherosclerotic Cardiovascular Diseases
Sites: Huntsville, Alabama; Cottonwood, Arizona; Phoenix, Arizona · 104 sites in all
- Assessment of the Long-Term Safety and Efficacy of Bempedoic Acid (CLEAR Harmony OLE)Pivotal-lookingCompleted
Esperion Therapeutics, Inc.Industry
NCT03067441 · 1,462 participants · Start Feb 3, 2017 · Primary completion Nov 5, 2019
Drug: bempedoic acid · For: Hypercholesterolemia; Atherosclerotic Cardiovascular Disease
Sites: Tampa, Florida; Louisville, Kentucky; Cincinnati, Ohio
- Carotid Ultrasound-Based Strategy for Primary Prevention of Cardiovascular Events in Inflammatory Rheumatic Disease (PREVENER)Pivotal-lookingRecruiting
Instituto de Investigación Marqués de ValdecillaAcademic, hospital or other
NCT07611747 · 1,117 participants (planned) · Start Apr 22, 2026 · Primary completion Apr 22, 2031
Drug: High-intensity lipid-lowering therapy · For: Rheumatoid Arthritis (RA); Psoriatic Arthritis (PsA); Systemic Lupus Erythematosus (SLE) and 4 more
Sites: Elche, Spain; Orihuela, Spain; Sant Joan d'Alacant, Spain · 17 sites in all
- Evaluation of Long-Term Efficacy of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia at High Cardiovascular RiskPivotal-lookingCompleted
Esperion Therapeutics, Inc.Industry
NCT02991118 · 779 participants · Start Nov 18, 2016 · Primary completion Aug 22, 2018
Drug: bempedoic acid; placebo · For: Hypercholesterolemia; Atherosclerotic Cardiovascular Disease
Sites: Clearwater, Florida; Georgetown, Texas
- Bempedoic Acid Versus Statins in Primary-Prevention Patients With Suboptimal Statin Adherence: Effects on LDL-C Reduction and TolerabilityPivotal-lookingNot yet recruiting
Sohaib AshrafAcademic, hospital or other
NCT07239414 · 690 participants (planned) · Start Nov 10, 2025 · Primary completion Nov 10, 2026
Drug: Bempedoic Acid 180 MG Oral Tablet; Rosuvastatin 5 mg and 1 more · For: Cardiovascular
- triPle Oral thERapy With Bempedoic Acid vs uSual Care in Early Lipid Management of Patients With acUte coronAry synDromEPivotal-lookingNot yet recruiting
Heart Care FoundationAcademic, hospital or other
NCT07440381 · 600 participants (planned) · Start Sep 2026 · Primary completion Aug 2027
Drug: Triple oral lipid lowering treatment · For: Acute Coronary Syndromes; Secondary Prevention; Lipids
Sites: Acquaviva delle Fonti, Italy; Altamura, Italy; Arezzo, Italy · 35 sites in all
- LATAM LOWERS LDL-CPivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT06501443 · 520 participants (planned) · Start Feb 11, 2025 · Primary completion Nov 27, 2026
Drug: Usual care; KJX839 · For: Hypercholesterolaemia
Sites: Corrientes, Argentina; Salvador, Brazil; Belo Horizonte, Brazil · 11 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- myalgia414
- arthralgia258
- muscle spasms174
- pain in extremity163
- nausea157
- dizziness142
- fatigue135
- headache130
- diarrhoea126
- blood creatine phosphokinase increased82
- gout82
- pain81
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2018 | 1 |
| 2019 | 6 |
| 2020 | 94 |
| 2021 | 210 |
| 2022 | 329 |
| 2023 | 393 |
| 2024 | 546 |
| 2025 | 583 |
| 2026 | 540 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Nexletol (Bempedoic Acid)
2024 spending
$70.9M
Beneficiaries
30,048
99,877 claims
Per beneficiary
$2,360
$13.08 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $3,144,324 |
| 2021 | $17,950,781 |
| 2022 | $28,969,645 |
| 2023 | $45,523,814 |
| 2024 | $70,919,860 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients.
Nissen SE, Lincoff AM, Brennan D, et al. · N Engl J Med 2023 · Randomized Controlled Trial
- Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol.
Ray KK, Bays HE, Catapano AL, et al. · N Engl J Med 2019 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Oral PCSK9 Inhibitor Enlicitide Versus Oral Nonstatin Therapies: A Phase 3 Randomized Clinical Trial.
Catapano AL, Mikhailova E, Navar AM, et al. · J Am Coll Cardiol 2026 · Randomized Controlled Trial, Clinical Trial, Phase III
- Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy.
Ballantyne CM, Laufs U, Ray KK, et al. · Eur J Prev Cardiol 2020 · Clinical Trial, Phase III, Multicenter Study
- Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance.
Laufs U, Banach M, Mancini GBJ, et al. · J Am Heart Assoc 2019 · Clinical Trial, Phase III, Multicenter Study
- Comparative Cardiovascular Benefits of Bempedoic Acid and Statin Drugs.
Lincoff AM, Ray KK, Sasiela WJ, et al. · J Am Coll Cardiol 2024 · Comparative Study, Randomized Controlled Trial
Sponsor: Esperion Theraps INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.